Health and Healthcare
Big Biotech: Best of 2010, Outlook in 2011 (ILMN, ITMN, INCY, THRX, VPHM, DNDN, AMGN, GILD, CELG, HGSI, ACOR)
Published:
Last Updated:
2010 is ending and 2011 is about to begin. It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there have been far fewer ten-baggers with more than 1,000% gains in 2010. Still, we have gone through a review of the “big biotechs” with a market cap cut off of $1 billion or higher. What we found was a series of the big 2010 winners and we also found which of the big biotech players may have the most upside ahead in 2011. Biohealth Investor has two separate groups reviewing those with the most implied upside for 2011 and also another showing those with best performance so far this year in 2010.
The big winners of 2010 have so far included shares of Illumina Inc. (NASDAQ: ILMN), InterMune Inc. (NASDAQ: ITMN), Incyte Corporation (NASDAQ: INCY), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM). We have taken a look at what has driven the gains as well as what the prospects are for 2011 and beyond. FULL REPORT
Dendreon Corporation (NASDAQ: DNDN) appears to have the most implied upside of the $1 billion and higher catgory, but others included are Amgen Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Human Genome Sciences, Inc. (NASDAQ: HGSI), Incyte Corporation (NASDAQ: INCY), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). The full list is available showing the implied upside and we have added color and commentary on each. FULL REPORT
Stay tuned for many more sector updates in many sectors with winners of 2010 and the outlook for 2011 and beyond!
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
